ASCO 2024 | Phase I trial of SX-682, a CXCR1/2 inhibitor, in metastatic melanoma
Sapna Patel, BA, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, remarks on a Phase I trial (NCT03161431) examining SX-682, a CXCR1/2 inhibitor, in combination with pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1 therapy. Patients received increasing doses of SX-682, with primary endpoints focusing on safety and tolerability, and secondary endpoints including objective response rate (ORR) and overall survival (OS). The results indicated a tolerable safety profile and encouraging clinical activity, with a notably longer median OS in this cohort. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Emory University
Consulting or Advisory Role – Bristol Myers Squibb; Cardinal Health; Castle Biosciences; Delcath Systems; IDEAYA Biosciences; immatics; Immunocore; MSD; Novartis; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers’ Bureau – BMS GmbH & Co. KG; MSD
Research Funding – Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses – BMS GmbH & Co. KG; Castle Biosciences; InxMed; TriSalus Life Sciences
